Glucose Variation Doesn't Affect Microvascular Complications

Share this content:
Glucose Variation Doesn't Affect Microvascular Complications
Glucose Variation Doesn't Affect Microvascular Complications

TUESDAY, April 18, 2017 (HealthDay News) -- Measures of glycemic variability in type 1 diabetes, based on complete quarterly 7-point glucose profiles, fail to provide evidence that glycemic variability contributes to the risk of development or progression of microvascular complications beyond the influence of mean glucose levels, according to a study published online April 12 in Diabetes Care.

John M. Lachin, Sc.D., from George Washington University in Rockville, Md., and colleagues utilized data from the Diabetes Control and Complications Trial to assess the association of glucose variability within and between quarterly 7-point glucose profiles and the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy.

The researchers found that adjusting for mean blood glucose, no measure of within-day variability was associated with any outcome. There was a significant association between the longitudinal mean M-value (over time) and microalbuminuria, when adjusted for the longitudinal mean blood glucose and corrected for multiple tests using the Holm procedure.

"Overall, within-day glycemic variability, as determined from quarterly glucose profiles, does not play an apparent role in the development of microvascular complications beyond the influence of the mean glucose," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »